** Shares of drug developer PepGen PEPG.O fall 27.4% to $3.40 premarket
** Co receives clinical hold notice from the US FDA regarding its mid-stage muscle disorder trial
** The FDA indicated they will provide an official clinical hold letter to the company within 30 days- PEPG
** The study was testing co's experimental drug, PGN-EDO51, in a 25-week clinical trial in patients with Duchenne muscular dystrophy
** Duchenne muscular dystrophy is a condition that causes skeletal and heart muscle weakness that quickly gets worse with time
** "We intend to work closely with the FDA to address their questions on our application to initiate CONNECT2 as expeditiously as possible," - PEPG
** Co says it continues to test PGN-EDO51 in the mid-stage trial in the 10 mg/kg group
** Up to last close, stock 31.2% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。